1. A behavioural science research programme to understand the barriers to achieving recommended LDL cholesterol goals. (August 2022) Authors: Clarke, A.L.; Bodini, S.; Douglas, L.; Catapano, A.L.; De Luca, L.; Hollstein, T.; Payne, J.; Pirro, M.; Viljoen, A.; Vogt, A.; Horne, R. Journal: Atherosclerosis Issue: Volume 355(2022) Page Start: 184 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Gene therapy: Case study on the first lipoprotein lipase deficiency patient treated with Alipogene Tiparvovec in Germany. (September 2016) Authors: Kassner, U.; Hollstein, T.; Wühle-Demuth, M.; Demuth, I.; Steinhagen-Thiessen, E. Journal: Atherosclerosis Issue: Volume 252(2016) Page Start: e83 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. PCSK9-Inhibitor treatment of cardiovascular high risk patients in clinical practice – New data regarding safety and effectivity. (August 2018) Authors: Hollstein, T.; Grenkowitz, T.; Scharnagl, H.; März, W.; Steinhagen-Thiessen, E.; Kassner, U. Journal: Atherosclerosis Issue: Volume 275(2018) Page Start: e31 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies (Pcsk9-I) Treatment Of Cardiovascular High Risk Patients In Clinical Practice. (August 2019) Authors: Kassner, U.; Hollstein, T.; Schumann, F.; Grenkowitz, T.; Scharnagl, H.; März, W.; Steinhagen-Thiessen, E. Journal: Atherosclerosis Issue: Volume 287(2019) Page Start: e212 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Short Report Of A Longterm Outcome Of A Patient With Lysosomal Acid Lipase Deficiency And First Results After Initiation Of Treatment With Sebelipase Alfa. (August 2019) Authors: Kassner, U.; Soll, D.; Hollstein, T.; Spira, D.; Bobbert, T.; Steinhagen-Thiessen, E. Journal: Atherosclerosis Issue: Volume 287(2019) Page Start: e202 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Treatment of therapy-refractory hypercholesterolemia with proprotein convertase subtilisin/kexin type 9 antibodies (PCSK9-I) in cardiovascular high risk patients – effectivity and safety in clinical routine. (September 2016) Authors: Hollstein, T.; Spira, D.; Buchmann, N.; El-Zidy Ibrahim, N.; Bobbert, T.; Steinhagen-Thiessen, E.; Kassner, U. Journal: Atherosclerosis Issue: Volume 252(2016) Page Start: e48 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Treatment With Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors (Pcsk9-I) In Clinical Routine – New Data Regarding Familial Hypercholesterolaemia (Fh) Genotype Safety And Efficacy. (August 2019) Authors: Schumann, F.; Hollstein, T.; Steinhagen-Thiessen, E.; Kassner, U. Journal: Atherosclerosis Issue: Volume 287(2019) Page Start: e215 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗